Clinical trial NCT00794144: Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Allergic Rhinitis
Keywords: Allergic Rhinitis
Pediatric
PATANASE
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2008-11-19
Enrollment: 132
Sex: ALL
Minimum age (years): 2
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of the study is to assess the safety of the study drug, Patanase (Olopatadine Hydrochloride Nasal Spray 0.6%) compared to placebo (inactive substance) in children ages 2 to less than 6 who have a history of nasal allergies, and to assess the pharmcokinetics (study of the action of a drug in the body) in these children


Eligibility criteria: Inclusion Criteria:

* Patient must be at least 2 years of age and less than 6 years of age on Day 1;
* Parent/legal guardian must be willing and able to give written informed consent and must provide this consent for the study;
* Patient must have a positive case history of allergic rhinitis symptoms and at least one documented positive skin test within the 5 years prior to Day 1 of the following type: skin prick test, intradermal test or RAST test(radioallergosorbent test) for an allergen (≥ 3 mm wheal greater than diluent after skin prick testing; ≥ 7 mm wheal greater than the diluent after intradermal testing; or positive level 2 or greater after RAST testing);
* Patient and parent/caregiver must be willing and able to make required study visits;
* Patient and parent/caregiver must be able to follow instructions;
* Nasal exam must confirm absence of significant anatomic abnormalities, infection, bleeding, and mucosal ulcerations at Screening and prior to administration of test article at the Day 1 Visit. A finding of 'present' for any of these parameters disqualifies the patient from the study, regardless of clinical relevance.

Exclusion Criteria:

* The need for chronic or intermittent use of any prescription or over-the-counter nasal spray during the study period;
* Use of any form of olopatadine (e.g., PATANOL®, PATADAY™, PATANASE®) within 7 days of Day 1;
* Current or recent (within the last 14 days) use of any drugs/drug classes or combinations thereof that may prolong the QT interval;
* Patients with a history or evidence of nasolacrimal drainage system malfunction or abnormality that may interfere with the results of the study;
* Concurrent disease that might complicate or interfere with the investigation or evaluation of the study medications (such as rhinitis medicamentosa or large obstructive nasal polyps);
* Patients with syndromes associated with midfacial deformities or other anatomic nasal deformity that may interfere with the patient's participation in the study, as identified by physical or nasal examination at Screening or Day 1;
* Diagnosis of acute sinusitis within 30 days of Day 1 or diagnosis of chronic rhinosinusitis within one year of Day 1;
* Congestion that would, in the opinion of the investigator, interfere with successful nasal drug administration/absorption (in either nostril);
* Upper or lower respiratory infection within 14 days of Day 1;
* Asthma, with the exception of intermittent asthma as outlined in Section 18.5, from the Stepwise Approach for Managing Asthma in Children 0-4 Years of Age, and Stepwise Approach for Managing Asthma in Children 5-11 Years of Age (5);
* Current or recent (\< 6 months) history of severe, unstable, or uncontrolled neurological, cardiovascular, gastrointestinal, hematological, hepatic, and/or renal disease, or evidence of other diseases at the physical examination conducted at the Screening Visit, which in the opinion of the Investigator would preclude the safe participation of the patient in the study;
* Hypersensitivity to olopatadine, benzalkonium chloride, or any component of the test articles;
* History or current infection of HIV (Human Immunodeficiency Virus), hepatitis B or C or A, as indicated by the patient's parent or legal guardian response on the HIV/Hepatitis survey;
* Relatives of study site staff or other individuals who would have access to the clinical study protocol;
* A family member or any individual residing in the same household of a patient that is currently enrolled in the study;
* Participation in any other investigational study within 30 days before entry into this study (Day 1), or concomitantly with this study;
* Clinically relevant abnormal vital signs (pulse rate, average systolic and diastolic blood pressure) at Screening or Day 1. The ranges below have been designated as normal for the study. Inclusion of patients with values outside of these normal ranges is at the discretion of the study investigator;

Normal Cardiovascular Ranges

* Systolic Blood Pressure - 86 to 116 mmHg (millimeters mercury)
* Diastolic Blood Pressure -50 to 78 mmHg
* Pulse - 75 to 130 bpm (beats per minute)

In addition, the Alcon Medical Monitor and/or Principal Investigator may declare any patient ineligible for the study based upon sound medical reasons.

Primary outcomes:
measure: Number of Participants With Anatomic Nasal Exam Abnormalities
timeFrame: Day 1 (Baseline) to Exit
Secondary outcomes:
Other outcomes:
Locations:
city: Waco
country: United States
facility: Niran Amar, M.D.
state: Texas
Study officials:
name: Niran Amar, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Spartanburg Medical Center
name: Sheri Byrd, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: National Allergy, Asthma, & Urticaria
name: Albert Finn, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Health Sciences Research Center
name: Joseph Flanagan, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Aeroallergy Research Laboratories
name: Brad H Goodman, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Central Texas Allergy and Asthma
name: Frank Hampel, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: West Coast Clinical Trials Phase 2-4
name: Yu-Luen Hsu, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Allergic Disease and Asthma Cente
name: Neil Kao, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Gulf Coast Research Associates, Inc
name: John Prestigiacomo, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Sylvana Research Associates
name: Paul Ratner, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Asthma and Allergy Associates, P.C.
name: Christopher Smith, MD
role: PRINCIPAL_INVESTIGATOR
References: